Abstract
A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (AALL1521/INCB18424-269): Biologic Characteristics and Minimal Residual Disease Response of Patients with Non-<i>CRLF2</i>-Rearranged JAK Pathway Alterations
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have